Search for:

The word or phrase you're searching for
Within sections:






The sections you wish to include in your search

Search Results

 
Displaying 1 - 10 of 32 results.
Cannabis for Medical Use - A Scientific Review
Cannabis for Medical Use - A Scientific Review,  31 JANUARY 2017 Cannabis for Medical Use - A Scientific Review Cannabis for Medical Use – A Scientific Review CONTENTS 1 EXECUTIVE SUMMARY, CANNABIS AND ITS REGULATION IN IRELAND 8 6 MEDICAL USE OF CANNABIS 9 7 SUMMARY OF SCIENTIFIC DATA ON EFFECTIVENESS 13 8 SUMMARY OF SCIENTIFIC DATA ON SAFETY 16 9 CANNABIS MISUSE 18 10 INTERNATIONAL PROGRAMMES FOR CANNABIS ACCESS 18 11 CONCLUSIONS 21 APPENDIX 1 MINISTER OF HEALTH’S LETTER
Medical Cannabis Access Programme
Medical Cannabis Access Programme, HPRA Website, My HPRA Logout Medical Cannabis Access Programme The Misuse of Drugs (Prescription and control of supply of cannabis for medical use) Regulations 2019 outline the legal framework and details of the Medical Cannabis Access Programme in Ireland. These Regulations enable the importation, prescribing and supply of cannabis-based products or preparations, known
Guide to Import and Export Licences and LONOs for Controlled Drugs (including the import of cannabis products)
of cannabis products),  AUT-G0127-8 20 DECEMBER 2022 This guide does not purport to be an interpretation, Licences and Letters of No Objection for Controlled Drugs (including the import of cannabis products, for Controlled Drugs (Including the Import of Cannabis Products) AUT-G0127-8 2/14 CONTENTS 1, APPLICATIONS FOR CANNABIS PRODUCTS OR PREPARATIONS TO BE CONSIDERED FOR INCLUSION IN SCHEDULE 1 OF THE MISUSE OF DRUG (PRESCRIPTION AND CONTROL OF SUPPLY OF CANNABIS FOR MEDICAL USE) REGULATIONS 2019 11
Cannabis for Medical Use – Controlled Access Advised
Cannabis for Medical Use – Controlled Access Advised,
Joint Committee on Health - HPRA statement on medical cannabis access programme
Joint Committee on Health - HPRA statement on medical cannabis access programme,
Application for products to be considered for inclusion in Schedule 1 of Misuse of Drugs Regulations 2019
(Prescription and control of supply of cannabis for medical use) Regulations 2019 On behalf, of Drugs (prescription and control of supply of cannabis for medical use) regulations 2019 Notes: The Misuse of Drugs (Prescription and control of supply of cannabis for medical use) Regulations 2019 outline the legal framework and details of the Medical Cannabis Access Programme (MCAP) in Ireland. These Regulations enable the importation, prescribing and supply of cannabis based products
Authority Report for meeting of 25 January 2017
to the members who complimented the new system. 8 Medicinal Cannabis Report An overview of work completed by the working group of experts, convened by the HPRA to discuss the matter of cannabis, . The main findings of the report are that the HPRA cannot recommend medicinal use of cannabis, the medical use of cannabis on the grounds of societal and public interest, the lack of efficacy and safety, decision be made, it should limit the access to cannabis to specified groups of patients
Legislation
stereoisomers” for “Cannabinol derivatives”, and (b) by substituting for “Cannabis (not being, (S.I. No. 173 of 2017))” the following: “Cannabis (not being a preparation specified in paragraph 5, of Cannabis for Medical Use) Regulations 2019 (S.I. No. 262 of 2019)) and permitted for supply pursuant, to the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019, cannabis products or preparations for medical use specified in Schedule 1 to the Misuse of Drugs
Authority Report for Meeting of 15 March 2017
. An overview was provided on the response to the HPRA report, Cannabis for Medical Use, in relation to medicinal cannabis for the purpose of implementing the access programme outlined within
Authority Report for the meeting of 6 June 2019
of the Authority. Specific points discussed included:  Cannabis for medical use: The Minister for Health is due to sign the legislation that will underpin the Medical Cannabis Access Programme in the coming